NAVIDEA BIOPHARMACEUTICALS, INC. (15)
Browse by Contract Category
Contracts
-
Form of Common Stock Purchase Agreement
(Filed With SEC on September 2, 2020)
-
Amended and Restated Equity Commitment Letter, dated August 14, 2020, between Mastiff Group LLC and Navidea Biopharmaceuticals, Inc
(Filed With SEC on August 14, 2020)
-
Employment Agreement, effective July 27, 2020, by and between Navidea Biopharmaceuticals, Inc. and Jed A. Latkin
(Filed With SEC on July 31, 2020)
-
Termination Agreement by and among the Company, SpePharm and Norgine
(Filed With SEC on May 12, 2020)
-
Stock Purchase Agreement and Letter of Investment Intent, by and between the Company and Keystone
(Filed With SEC on September 2, 2020)
-
Stock Purchase Agreement, effective August 9, 2020, by and between Navidea Biopharmaceuticals, Inc. and Jubilant Radiopharma
(Filed With SEC on August 12, 2020)
-
Stock Purchase Agreement and Letter of Investment Intent by and between the Company and the Investor
(Filed With SEC on May 12, 2020)
-
Stock Purchase Agreement, effective February 14, 2020, by and between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC
(Filed With SEC on March 18, 2020)
-
Description of Securities
(Filed With SEC on March 18, 2020)
-
Stock Purchase Agreement, effective February 14, 2020, by and between Navidea Biopharmaceuticals, Inc. and John K. Scott
(Filed With SEC on March 18, 2020)
-
Registration Rights Agreement, dated December 6, 2019, among Navidea Biopharmaceuticals, Inc. and the stockholders named therein
(Filed With SEC on December 11, 2019)
-
Stock Purchase Agreement, dated December 6, 2019, among Navidea Biopharmaceuticals, Inc. and the purchasers named therein
(Filed With SEC on December 11, 2019)
-
Underwriting Agreement, dated June 13, 2019, by and between Navidea Biopharmaceuticals, Inc. and H.C. Wainwright & Co., LLC
(Filed With SEC on June 17, 2019)
-
Form of Underwriter Warrants of Navidea Biopharmaceuticals, Inc
(Filed With SEC on June 17, 2019)
-
Stock Purchase Agreement, dated March 22, 2019, between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr
(Filed With SEC on May 9, 2019)